Poražavajuća statistika: Traži se sistemsko rešenje za borbu protiv raka grlića materice
Prema najnovijem izveštaju Švedskog instituta za zdravstvenu ekonomiju (IHE), u Srbiji je tokom 2022. godine registrovano 1.060 novih slučajeva i 404 smrtna ishoda od raka grlića materice. Više od polovine preminulih žena bilo je mlađe od 65 godina.
TL;DR
- In 2022, Serbia recorded 1,060 new cervical cancer cases and 404 deaths, with over half of the deceased women being under 65.
- In 2019, cervical cancer resulted in 7,705 lost years of life and 2,544 lost years of productive life, with an estimated annual economic loss of 8.8 million euros.
- Patient organizations have requested the establishment of a special budget line for innovative oncological therapies from 2026.
- Only 14% of oncology drugs approved by the EMA between 2020-2023 were available in Serbia by early 2025, compared to the EU average of 50%.
- Despite announcements of significant investment in innovative therapies, the Central Commission of the RFZO has not met for two years, preventing the inclusion of new drugs.
- Prevention through vaccination and screening is highlighted as crucial, along with organized registries for tracking and follow-up.
- There is a call for systemic solutions to ensure sufficient and sustainable financing for innovative drugs through the Positive List.
- The initiative has garnered support from various professional associations and patient organizations.